We're excited to announce that the first part of the BIG Trial in gastric cancer, powered by the incredible team at GERCOR, has hit its recruitment goal!

Patients are now being monitored after receiving EXL01, our novel NOD2-targeting biotherapeutic, in combination with nivolumab (anti-PD-L1) plus FOLFOX (chemotherapy).

Following the DSMB review and a submission to ANSM, part 2 could start in Q3 2025.

EXL01 is designed to reprogram macrophages and enhance checkpoint inhibitor efficacy - aiming to raise the bar in first-line gastric cancer.

The BIG study is more than a trial — it’s a potential turning point for patients, for Exeliom and for the microbiome field. More information on this trial (NCT0625361) can be found on clinicaltrial.gov

Stay tuned for more updates as we advance through this clinical trial!